Lidocaine Accord (Lidocaine Hydrochloride)

Lidocaine acts by binding to voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel. This prevents sodium influx required for depolarization, thereby inhibiting the generation and propagation of action potentials. The result is a reversible blockade of sensory and motor nerve signals, producing localized anesthesia and analgesia.

The dosage of Lidocaine Accord is determined by the prescribing clinician based on the specific procedure, route of administration, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate amount to achieve effective anesthesia while minimizing the risk of toxicity. Exact dosing regimens are not provided here.

Safety data for lidocaine during pregnancy and lactation are limited. It may be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should consider alternative agents and follow local regulatory guidance. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lidocaine Accord. GNH India works with hospitals, pharmacies, and procurement teams worldwide, requesting verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidocaine has a relatively rapid onset (1–3 minutes) and intermediate duration (30–120 minutes) compared with agents such as bupivacaine, which has a slower onset but longer duration. Lidocaine offers a favorable safety profile and is widely used for short‑ to medium‑duration procedures, whereas bupivacaine is preferred for prolonged analgesia. Choice depends on procedural length, required depth of block, and patient factors.

Lidocaine Accord should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Once the vial is opened, use according to aseptic technique and discard any remaining solution after the recommended in‑use period to maintain sterility.

Lidocaine Accord is administered by a qualified healthcare professional via epidural, intramuscular, or intravenous injection, depending on the clinical indication. The injection site is prepared aseptically, and the dose is titrated to achieve the desired level of anesthesia while monitoring the patient for signs of toxicity throughout the procedure.

Serious adverse events include central nervous system toxicity such as seizures, cardiovascular complications like arrhythmias or cardiac arrest, severe allergic reactions (anaphylaxis), methemoglobinemia, and profound hypotension or respiratory depression. Prompt recognition and supportive management are essential if any of these events occur.

Lidocaine Accord is contraindicated in patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block or uncontrolled arrhythmias, and individuals with significant hepatic impairment that cannot be medically managed. Caution is also advised for patients with a history of seizures or methemoglobinemia.